After rallying 52% in a month, can Piramal Enterprises sustain its momentum?
The company's management has guided for a 15% organic revenue growth in the pharma business for FY22 compared with the 1% growth in the first nine months of FY21. PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Investor and Analyst Call for Piramal Enterprises
Conference Call with Piramal Enterprises Management and Analysts on the company's overall performance and outlook. Watch the full transcript. PIRAMAL ENTERPRISES LTD. - 500302 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Virtual Conference/ Meeting with Investors/ Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 PIRAMAL ENTERPRISES LTD. - 500302 - Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed the investor presentation to be made to Analyst/Institutional Investors under Regulation 30 of the Listing Regulations. Pursuant to Regulation 46 of the Listing Regulations, the presentation is also hosted on the website of the Company i.e. www.piramal.com. Piramal Enterprises sets up new alternative fund management business
Piramal has roped in Kalpesh Kikani as Chief Executive Officer PIRAMAL ENTERPRISES LTD. - 500302 - Intimation Under Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, As Amended And Securities And Exchange Board Of India'S Circular No. CIR/CFD/CMD/4/2015 Dated September 9, 2015
We had, vide our letter dated 28th October, 2020, made a disclosure regarding the acquisition of additional stake in Convergence Chemicals Private Limited ('CCPL') for an aggregate cash consideration of Rs.65.10 crores by Piramal Pharma Limited ('PPL'), subsidiary of the Company ('Transaction'). We wish to inform you that PPL has completed the acquisition of CCPL on 24th February, 2021 and the Transaction is now closed. This is for your information and records.